IBS-D patients and investigators interested in participating in our trial, please visit prevailibsdstudy.com.
OrphoMed is a clinical-stage company with a proprietary dimer therapeutics platform. Our current focus is on developing therapies for irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis.